Eisai R&d Management Co., Ltd.

Eisai Inc.

Sergei I Agoulnik

John JianShi Wang

Yimin Jiang

Xiang-Yi Li

Huiming Zhang

Hong Du

Bruce Decosta

Kenichi Nomoto

John (Yuan) Wang

Jiayi Wu

Jean-Christophe P Harmange

Lynn D Hawkins

Shawn Schiller

Frank Fang

Bruce A Littlefield

Charles W Johannes

Pamela McGuiness

Mary Vermeulen

Michael Chapman Byrne

Kozo Akasaka

Erin A Murphy

John (yuan) Wang

John Wang

The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): wherein R-Rare as defined herein, or pharmaceutically acceptable salts or esters thereof; and a pharmaceutically acceptable carrier.

Multikinase inhibitors for use in the treatment of cancer

The invention provides methods for predicting the efficacy of eribulin, an analog thereof, or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate), in the treatment of a subject suffering from breast cancer by determining the level of particular biomarkers in a sample derived from the subject.

Methods and compositions for predicting response to eribulin

The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): 

The present invention provides compounds having formula (1): wherein R-R, A, J, D, E, G, Q, w, x, y, and z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of cancer and/or inflammatory disorders, and more generally as proteasome inhibitors.

Eponemycin and epoxomicin analogs and uses thereof

Growing community of inventors

Andover, MA, United States of America

Sergei I Agoulnik